Neoadjuvant chemotherapy as ovarian cancer treatment: ever more used with major regional differences
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
The traditional first-line treatment for patients with advanced ovarian cancer with primary debulking surgery (PDS) and adjuvant chemotherapy is controversial as some authors report a potential benefit from the alternative treatment with neoadjuvant chemotherapy (NACT) and interval debulking surgery. The aim of this study was to investigate the use of NACT in Denmark in regard to increased use and regional differences.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Danish Medical Journal |
Vol/bind | 59 |
Udgave nummer | 8 |
Sider (fra-til) | A4477 |
Antal sider | 5 |
Status | Udgivet - 2012 |
ID: 40161262